Targeting of tumor growth and angiogenesis underlies the enhanced antitumor activity of lenvatinib in combination with everolimus-Reference-Cited by-同舟云学术

Targeting of tumor growth and angiogenesis underlies the enhanced antitumor activity of lenvatinib in combination with everolimus

Published:2017-04 Issue:4 Volume:108 Page:763-771
ISSN:1347-9032
Container-title:Cancer Science
language:en
Short-container-title:Cancer Sci

Author:

Matsuki Masahiro¹,Adachi Yusuke¹,Ozawa Yoichi¹,Kimura Takayuki¹,Hoshi Taisuke¹,Okamoto Kiyoshi¹,Tohyama Osamu¹,Mitsuhashi Kaoru¹,Yamaguchi Atsumi¹,Matsui Junji¹,Funahashi Yasuhiro¹

Affiliation:

1. Tsukuba Research Laboratories; Eisai Co., Ltd.; Tsukuba Ibaraki Japan

Funder

Eisai

Publisher

Wiley

Subject

Cancer Research,Oncology,General Medicine

Link

http://onlinelibrary.wiley.com/wol1/doi/10.1111/cas.13169/fullpdf

Reference37 articles.

1. Lenvatinib versus placebo in radioiodine-refractory thyroid cancer;Schlumberger;N Engl J Med,2015

2. E7080, a novel inhibitor that targets multiple kinases, has potent antitumor activities against stem cell factor producing human small cell lung cancer H146, based on angiogenesis inhibition;Matsui;Int J Cancer,2008

3. Multi-kinase inhibitor E7080 suppresses lymph node and lung metastases of human mammary breast tumor MDA-MB-231 via inhibition of vascular endothelial growth factor-receptor (VEGF-R) 2 and VEGF-R3 kinase;Matsui;Clin Cancer Res,2008

4. Antitumor activities of the targeted multi-tyrosine kinase inhibitor lenvatinib (E7080) against RET gene fusion-driven tumor models;Okamoto;Cancer Lett,2013

5. Antitumor activity of lenvatinib (e7080): an angiogenesis inhibitor that targets multiple receptor tyrosine kinases in preclinical human thyroid cancer models;Tohyama;J Thyroid Res,2014

Cited by 58 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. PRELP inhibits colorectal cancer progression by suppressing epithelial-mesenchymal transition and angiogenesis via the inactivation of the FGF1/PI3K/AKT pathway;Apoptosis;2024-09-06

2. Receptor tyrosine kinase inhibition leads to regression of acral melanoma by targeting the tumor microenvironment;2024-06-17

3. Tumor biomarkers for diagnosis, prognosis and targeted therapy;Signal Transduction and Targeted Therapy;2024-05-20

4. The effectiveness of the combination of lenvatinib and everolimus in metastatic renal cell carcinoma in patients with resistance to targeted treatment in real clinical practice;Medical alphabet;2024-05-09

5. Discovery and Validation of a 15-Gene Prognostic Signature for Clear Cell Renal Cell Carcinoma;JCO Precision Oncology;2024-05